pseudovirus
use
virolog
tool
safeti
versatil
especi
emerg
reemerg
virus
due
high
pathogen
infect
lack
effect
vaccin
therapeut
live
handl
biosafeti
level
condit
hinder
develop
vaccin
therapeut
base
vsv
pseudoviru
product
system
pseudovirusbas
neutral
assay
develop
evalu
neutral
antibodi
biosafeti
level
facil
key
paramet
assay
optim
includ
cell
type
cell
number
viru
inoculum
test
pseudoviru
convalesc
patient
sera
show
high
neutral
potenc
underscor
potenti
therapeut
limit
detect
assay
determin
human
mous
serum
sampl
respect
use
panel
neg
sampl
cutoff
valu
set
human
mous
serum
sampl
respect
assay
show
rel
low
coeffici
variat
intraand
interassay
analys
respect
taken
togeth
establish
robust
pseudovirusbas
neutral
assay
glad
share
pseudovirus
relat
protocol
develop
vaccin
therapeut
fight
lethal
viru
coronaviru
member
coronaviru
subfamili
coronavirida
host
rich
vari
addit
human
be
coronaviru
also
infect
mani
kind
mammal
bird
coronavirus
caus
diseas
human
livestock
poultri
six
known
human
coronavirus
belong
caus
respiratori
diseas
differ
sever
includ
four
common
coronavirus
two
highli
pathogen
emerg
coronavirus
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
decemb
unexplain
pneumonia
later
name
coronaviru
diseas
broke
wuhan
china
initi
patient
relat
seafood
wholesal
market
wuhan
new
type
found
unbias
highthroughput
sequenc
sampl
patient
pneumonia
new
type
coronaviru
isol
human
respiratori
epitheli
cell
belong
subgenu
sabeviru
subfamili
coronaviru
differ
previous
isol
merscov
sarscov
viru
seventh
coronaviru
infect
human
name
coronaviru
envelop
viru
four
structur
protein
spike
protein
membran
protein
envelop
e
protein
nucleocapsid
n
protein
protein
respons
viru
attach
entri
target
cell
initi
infect
process
protein
play
key
role
induct
protect
humor
cellular
immun
sarscov
infect
consequ
protein
consid
attract
target
sarscov
vaccin
therapeut
develop
face
novel
coronaviru
pneumonia
epidem
varieti
approach
employ
develop
prophylact
therapeut
measur
includ
whole
inactiv
vaccin
subunit
vaccin
rnabas
vaccin
viral
vector
vaccin
monoclon
neutral
antibodi
fusion
inhibitor
design
target
protein
howev
due
high
infect
pathogen
handl
biosafeti
level
facil
limit
develop
antivir
measur
access
live
viru
stain
anoth
major
barrier
develop
candid
vaccin
therapeut
avoid
deal
infecti
viru
develop
seri
pseudovirusbas
neutral
assay
pbna
emerg
reemerg
virus
includ
merscov
rabi
viru
ebola
viru
marburg
viru
lassa
viru
chikungunya
viru
nipah
viru
rift
valley
viru
other
commun
develop
pbna
evalu
antivir
measur
would
use
evalu
inhibit
viral
attach
entri
mediat
protein
pseudovirus
protocol
pbna
readi
share
research
team
manufactur
engag
develop
antivir
product
vsv
g
specif
antibodi
gener
immun
balbc
mous
vsv
g
express
plasmid
amount
ten
mice
immun
three
time
two
week
interv
two
week
final
inject
serum
sampl
ten
mice
collect
pool
togeth
vsv
g
specif
antibodi
sampl
mice
hous
maintain
accord
relev
guidelin
regul
two
serum
sampl
convalesc
patient
gener
provid
mr
qiang
gao
sinovac
biotech
co
ltd
written
inform
consent
obtain
volunt
pseudovirus
construct
spike
gene
strain
genbank
codonoptim
human
cell
clone
eukaryot
express
plasmid
gener
envelop
recombin
plasmid
pseudovirus
produc
titrat
use
method
similar
rift
valley
fever
pseudoviru
describ
previous
vsv
pseudoviru
system
backbon
provid
vsv
g
pseudotyp
viru
g
packag
express
cassett
firefli
luciferas
instead
vsvg
vsv
genom
briefli
cell
transfect
flask
use
lipofectamin
invitrogen
follow
manufactur
instruct
twentyfour
hour
later
transfect
cell
infect
g
multipl
four
two
hour
infect
cell
wash
pb
three
time
new
complet
cultur
medium
ad
twentyfour
hour
post
infect
pseudovirus
contain
cultur
supernat
harvest
filter
pore
size
millipor
store
aliquot
use
tissu
cultur
infecti
dose
tcid
pseudoviru
determin
use
singleus
aliquot
pseudoviru
bank
stock
use
avoid
inconsist
could
result
repeat
freezingthaw
cycl
titrat
pseudoviru
initi
dilut
made
hexapl
well
cultur
plate
follow
serial
dilut
nine
dilut
total
last
column
serv
cell
control
without
addit
pseudoviru
plate
seed
trypsintr
mammalian
cell
adjust
predefin
concentr
h
incub
co
environ
cultur
supernat
aspir
gentli
leav
well
luciferas
substrat
perkinelm
ad
well
two
min
incub
room
temperatur
lysat
transfer
white
solid
plate
detect
luminesc
use
micropl
luminomet
perkinelm
ensight
posit
well
determin
tenfold
rel
luminesc
unit
rlu
valu
higher
cell
background
tissu
cultur
infecti
dose
tcid
calcul
use
reedmuench
method
describ
previous
seven
millilitr
pseudovirus
titr
tcid
ml
pellet
sucros
cushion
ultracentrifug
g
h
layer
supernat
sucros
remov
result
viral
pellet
resuspend
pb
sixti
microlitr
prepar
pseudovirus
mix
sdssampl
buffer
mixtur
heat
min
fifteen
microlitr
sampl
subject
sdspage
immunoblot
vsv
pseudotyp
viru
prepar
procedur
use
pseudoviru
neg
control
cell
cultur
medium
neg
control
incorpor
spike
protein
pseudoviru
surfac
confirm
use
western
bolt
convalesc
serum
sampl
detect
antibodi
dilut
goat
antihuman
igg
jackson
immunoresearch
use
dilut
secondari
antibodi
neutral
measur
reduct
luc
gene
express
describ
previous
hiv
pseudoviru
neutral
assay
inhibitori
dilut
ec
defin
serum
dilut
rel
light
unit
rlu
reduc
compar
viru
control
well
viru
cell
subtract
background
rlu
control
group
cell
brief
pseudoviru
incub
serial
dilut
test
sampl
six
dilut
stepwis
manner
duplic
h
togeth
viru
control
cell
control
well
hexapl
freshli
trypsin
cell
ad
well
follow
h
incub
co
environ
luminesc
measur
describ
section
pseudoviru
titrat
ec
valu
calcul
nonlinear
regress
ie
log
inhibitor
vs
respons
four
paramet
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
usa
construct
recombin
plasmid
express
spike
protein
gener
pseudotyp
viru
optim
fulllength
gene
strain
genbank
insert
get
vesicular
stomat
viru
vsv
pseudoviru
system
employ
produc
pseudoviru
expect
present
spike
protein
surfac
vsv
particl
verifi
incorpor
spike
protein
surfac
protein
pseudoviru
detect
use
westernblot
convalesc
patient
sera
shown
figur
specif
band
could
found
lane
pseudoviru
whilst
specif
band
found
medium
control
vsv
pseudoviru
correspond
posit
gener
procedur
pseudoviru
monom
protein
observ
posit
kda
result
confirm
kda
kda
polypeptid
correspond
domain
respect
band
posit
around
kda
observ
lane
vsv
pseudoviru
may
attribut
share
vsv
core
two
pseudovirus
pseudoviru
togeth
g
test
vsv
g
specif
antibodi
figur
b
pseudoviru
could
neutral
vsv
g
serum
dilut
almost
complet
inhibit
g
infect
indic
almost
g
mix
pseudoviru
stock
gener
pseudotyp
viru
next
set
investig
cell
type
pseudoviru
entri
widetyp
success
isol
vero
monkey
kidney
cell
human
hepatoma
cell
two
similar
cell
line
human
kidney
cell
similar
vero
hep
human
hepatoma
cell
similar
also
includ
target
cell
investig
addit
anoth
two
mammal
cell
line
also
employ
target
cell
select
includ
cho
chines
hamster
ovari
cell
mdck
dog
kidney
cell
wide
employ
recombin
protein
vaccin
product
taken
togeth
six
type
cell
test
figur
expect
cell
line
show
high
suscept
vsv
pseudotyp
viru
vero
show
high
suscept
pseudotyp
similar
sarscov
report
previous
cell
identifi
best
cell
substrat
pseudoviru
infect
yield
highest
signal
next
determin
optim
number
cell
pseudoviru
infect
toward
end
titrat
pseudotyp
viru
rang
cell
number
well
highest
titr
observ
rang
well
equal
amount
pseudoviru
prepar
test
figur
note
linear
correl
coeffici
r
obtain
cell
inoculum
well
found
greater
reveal
excel
linear
curv
fit
moreov
neutral
assay
perform
differ
cell
inocula
ec
valu
similar
cell
number
rang
well
figur
b
howev
input
cell
number
well
r
valu
titrat
inhibit
assay
would
decreas
dramat
given
find
chose
well
subsequ
experi
although
nonspecif
respons
observ
vari
cell
number
condit
inhibit
pseudoviru
reach
normal
human
serum
sampl
figur
b
next
test
viral
inocula
dose
rang
start
tcid
well
pbna
expect
absolut
ec
valu
decreas
gradual
increas
amount
viral
inocula
figur
viru
dose
lower
tcid
well
curv
fit
valu
would
decreas
significantli
therefor
viral
inocula
tcid
well
use
optim
dose
although
nonspecif
respons
observ
vari
viral
inocula
inhibit
rate
pseudoviru
reach
normal
human
serum
sampl
figur
pbna
assay
would
intend
use
analys
human
anim
sampl
neg
sampl
panel
seventyfour
human
fortysix
mous
sera
use
determin
specif
assay
initi
dilut
follow
serial
dilut
first
establish
limit
detect
lod
pbna
assay
shown
figur
assay
pbna
human
neg
serum
sampl
show
rel
low
background
compar
mous
neg
sampl
mean
titr
valu
neg
sampl
standard
deviat
sd
use
calcul
limit
detect
lod
lod
human
serum
sampl
mous
serum
sampl
cutoff
valu
set
human
mous
serum
sampl
respect
nonspecif
background
mous
sera
higher
human
serum
sampl
unexpect
reason
higher
background
mous
sera
would
investig
futur
studi
linear
rang
mean
direct
correl
signal
concentr
substanc
within
specif
rang
determin
linear
rang
pbna
two
convalesc
patient
serum
sampl
test
pseudoviru
typic
fourparamet
inhibit
curv
observ
two
posit
sampl
logtransform
dilut
inhibit
rate
figur
b
inhibit
rate
rang
linear
relationship
readout
test
sampl
dilut
posit
sampl
r
figur
c
nonspecif
inhibit
observ
human
mous
neg
serum
sampl
lower
dilut
figur
b
order
test
reproduc
pbna
two
coalesc
patient
serum
sampl
pool
togeth
use
test
pseudoviru
sampl
test
total
time
individu
plate
three
independ
run
figur
averag
coeffici
variat
cv
intraand
interassay
respect
accept
cellbas
assay
collect
data
indic
robust
pbna
assay
establish
test
entri
inhibit
could
use
evalu
candid
vaccin
therapeut
target
viru
entri
current
evalu
assay
vaccin
therapeut
requir
use
isol
live
viru
must
handl
level
biocontain
facil
addit
live
viru
assay
take
least
three
day
known
labour
intens
clearli
explor
altern
method
facilit
develop
evalu
vaccin
therapeut
target
viru
entri
target
cell
pseudovirusbas
neutral
assay
pbna
offer
great
advantag
widetyp
virusbas
method
versatil
much
safer
handl
versatil
pseudoviru
achiev
pseudotyp
viru
differ
outer
membran
protein
envelop
protein
mimick
infecti
process
live
viru
provid
envelop
protein
pseudoviru
much
safer
viru
essenti
devoid
virul
viral
compon
involv
singl
round
replic
respect
valid
neutral
assay
pbna
sensit
accur
reproduc
robust
method
compar
live
viru
assay
pbna
object
less
labour
intens
data
obtain
luminesc
read
oper
live
viru
assay
read
result
manual
microscop
howev
ec
valu
serum
sampl
would
chang
variat
pseudoviru
inoculum
import
fix
pseudoviru
dose
make
result
compar
differ
laboratori
besid
antibodi
standard
develop
schedul
near
futur
minim
variat
data
obtain
differ
team
short
absenc
lethal
wide
type
viru
experiment
procedur
could
greatli
facilit
develop
vaccin
therapeut
would
like
provid
pseudoviru
relat
protocol
vaccin
therapeut
develop
evalu
candid
product
neg
sampl
panel
seventyfour
human
fortysix
mous
serum
sampl
use
determin
specif
assay
b
inhibit
curv
two
convalesc
patient
serum
sampl
two
neg
serum
sampl
deriv
human
mous
typic
fourparamet
inhibit
curv
observ
two
sampl
logtransform
dilut
inhibit
rate
initi
dilut
posit
neg
sampl
respect
follow
serial
dilut
c
linear
rang
pbna
inhibit
rate
rang
linear
relationship
readout
test
sampl
dilut
reproduc
pbna
mixtur
two
coalesc
patient
serum
sampl
test
total
time
individu
plate
three
independ
run
